Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB-403 in pediatric relapsed/refractory solid tumors
NCT02748135Phase 1Completed
- Sponsor
- Oncurious NV
- Start
- May 2016
- Primary completion
- Oct 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of THR-317 in medulloblastoma, neuroblastoma, Ewing sarcoma and 1 more (4 arms), sponsored by Oncurious NV. Primary endpoint: Maximum Tolerated Dose at Day 28. Started May 2016; status: completed.
02
Drugs
THR-317
03
Conditions
medulloblastomaneuroblastomaEwing sarcomaalveolar rhabdomyosarcoma (ARMS)
Beyond the preview
Go deeper on NCT02748135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748135.